Global Temsirolimus Drug Market Size, Share and Trends Analysis Report, By Disease (Renal Cell Carcinoma, Breast Cancer, Rheumatoid Arthritis and Multiple Myeloma), By End-User) (Hospital, Clinics, and Other), Forecast (2022-2028)

The temsirolimus drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Temsirolimus drug is used for the treatment of renal cell carcinoma. Renal cell carcinoma is a type of cancer that starts from the kidney. Temsirolimus drug is a type of drug which comes under medications known as kinase inhibitors. Abnormal proteins support cancer cells to multiply, temsirolimus works on those proteins and blocks their action. This makes cancer cells stop growing abruptly. After this action of blocking is done, the tumor which grows in the body stops to grow. This drug is also helpful in the treatment of breast cancer, rheumatoid arthritis, and multiple myeloma. This drug is usually given through injections into the veins directly. Dosages are once a week in most cases. Side effects of this drug include rash, itching, difficulty in breathing and swallowing, and chest pain. This drug is an inhibitor of the mammalian target of rapamycin. An intracellular protein known as FKBP-12 binds itself to the temsirolimus drug which further controls cancer cells. This resulted in reduced activity levels of HIF-1 and HIF-2 alpha which are potential hypoxia-inducible factors.

Investment in oncology medicines by pharma companies is expected to drive the market during the forecast period. For instance, in May 2021, Fresenius Kabi in the US will now make available temsirolimus drug in injectable form. This drug is mainly used for the treatment of renal cancer. According to the company, this drug is a new addition to the company’s portfolio of generic injectable oncology products. This drug will be given as a kit containing one vial of diluent. The major aim of the company for launching this product is to increase their reach more and have expertise in cancer treatment drugs. The company also offers biosimilars in the oncology segment for cost-effective treatment of cancer disease. Temsirolimus drugs have been found useful in other health conditions as well. For instance, in Oct 2020, phase 2 clinical studies and trials have found that temsirolimus drug is effective in reducing neointimal hyperplasia. This study was presented at TCT connect 2020. Through the deployment of a microinfusion system, temsirolimus can prove effective in coronary circulation.

Some major players in the market are Pfizer Inc., Novartis International AG, and Biocon Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Allarity Therapeuics Inc. has announced that it has submitted a drug application to Food and Drug Administration in the US for the approval of dovitinib. This drug would be useful in the treatment of renal cell carcinoma. Earlier the company has also applied for the approval of Dovitinib-DRP which includes selecting patients with renal cell carcinoma and treating them with this agent. The company is making a mark for the treatment line in cancer-related therapeutics.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., Novartis International AG, and Biocon Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Temsirolimus Drug Market Report by Segment

By Disease

• Renal Cell Carcinoma
• Breast Cancer
• Rheumatoid Arthritis
• Multiple Myeloma

By  End-User

• Hospitals
• Clinics
• Others

Global Temsirolimus Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa